Overview

Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations

Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
0
Participant gender:
All
Summary
Postoperative nausea and vomiting (PONV) is one of the most common and distressing complications after anaesthesia and surgery, and may lead to serious postoperative complications This prospective, randomized study designed to evaluate the best injection time to get the prophylactic anti-emetic efficacy of ramosetron, a newly developed 5-HT(3) antagonist in patients undergoing facial bone surgery.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Ramosetron
Criteria
Inclusion Criteria:

- Patient who sign informed consent form for the study

- patient who are considered as surgical candidates with facial bones fracture

Exclusion Criteria:

- Patient who have had nausea/vomiting episodes